IRIS
MARABOTTO, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 10.651
AS - Asia 185
SA - Sud America 68
NA - Nord America 14
AF - Africa 2
Totale 10.920
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 10.643
CN - Cina 111
BR - Brasile 52
VN - Vietnam 33
SG - Singapore 18
US - Stati Uniti d'America 14
ID - Indonesia 8
HK - Hong Kong 6
EC - Ecuador 5
AR - Argentina 4
CL - Cile 3
UA - Ucraina 3
BD - Bangladesh 2
DE - Germania 2
PH - Filippine 2
PY - Paraguay 2
AZ - Azerbaigian 1
CO - Colombia 1
FR - Francia 1
GB - Regno Unito 1
IN - India 1
IQ - Iraq 1
JO - Giordania 1
PE - Perù 1
RU - Federazione Russa 1
SN - Senegal 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 10.920
Salva come PNG Salva come JPEG
Città #
Genova 5.006
Genoa 3.881
Vado Ligure 897
Rapallo 830
Beijing 50
Bordighera 21
Singapore 16
Ho Chi Minh City 13
Ashburn 12
Hanoi 7
Hong Kong 6
São Paulo 5
Tianjin 4
Milan 3
Rio de Janeiro 3
Thái Bình 3
Asunción 2
Cachoeira do Sul 2
Concepción 2
Curitiba 2
Hanau 2
Hải Dương 2
Mediglia 2
Ninh Bình 2
Amman 1
Artur Nogueira 1
Atibaia 1
Baku 1
Batam 1
Bauru 1
Betim 1
Biên Hòa 1
Bogotá 1
Boisar 1
Bologna 1
Bonito de Santa Fé 1
Brumado 1
Buenos Aires 1
Cajamar 1
Campo Largo 1
Carpina 1
Cebu City 1
Cerquilho 1
Chacabuco 1
Changsha 1
Congonhas 1
Cuenca 1
Dakar 1
Depok 1
Estación Colina 1
Fortaleza 1
Foz do Iguaçu 1
Goiânia 1
Groblersdal 1
Guarulhos 1
Guayaquil 1
Haiphong 1
Irkutsk 1
Itanhaém 1
Itaquiraí 1
Jundiaí 1
Kharkiv 1
Lagoa Santa 1
Lima 1
Limeira 1
Los Angeles 1
Lviv 1
Machala 1
Makassar 1
Manaus 1
Manta 1
Marabá 1
Mauá 1
Milton Keynes 1
Nasiriyah 1
Padre Paraíso 1
Palembang 1
Parnaíba 1
Passo Fundo 1
Pekanbaru 1
Porto Alegre 1
Probolinggo 1
Quito 1
Recife 1
Rio do Antônio 1
San Miguel de Tucumán 1
Santa Cruz do Capibaribe 1
Santa Luzia 1
Santa Maria da Vitória 1
Santos 1
Sertãozinho 1
Sorocaba 1
São José dos Campos 1
Tashkent 1
Valparaíso de Goiás 1
Vargem Grande Paulista 1
Victoria 1
Volta Redonda 1
Wuhan 1
Xinguara 1
Totale 10.849
Salva come PNG Salva come JPEG
Nome #
Characteristics of gastro-esophageal reflux episodes in Barrett's esophagus, erosive esophagitis and healthy volunteers 196
Proton pump inhibitors: use and misuse in the clinical setting 192
Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. 181
Advancements in the use of manometry and impedance testing for esophageal functional disorders 177
Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index 173
A safety review of proton pump inhibitors to treat acid-related digestive diseases 171
A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD) 167
Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease 165
The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. 164
Measurement of oro-caecal transit time by magnetic resonance imaging. 163
Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. 160
Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. 157
Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease. 155
Drugs for improving esophageal mucosa defense: Where are we now and where are we going? 154
Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease 151
A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients 149
Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease. 147
Anti-TNF Antibodies For Prevention of Crohn's Disease Recurrence After Surgery: More Than An Hope. 146
Hepatocellular carcinoma in patients with cryptogenic cirrhosis 144
Microscopic Esophagitis is More Frequent in Patients With pH-Positive Non-Erosive Reflux Disease and Hypersensitive Esophagus Than in Those With Functional Heartburn: A Study Using Impedance-pH and Optical Microscopy. 143
Optimal management of constipation associated with irritable bowel syndrome. 138
Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: the perfect storm 135
Comment on "impairment of chemical clearance is relevant to the pathogenesis of refractory reflux oesophagitis" by Marzio Frazzoni et al. [Digestive and Liver Disease 2014;46:596-602]. 134
Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations 133
The appropriate use of proton-pump inhibitors 132
Reduction of hexavalent chromium by fasted and fed human gastric fluid. I. Chemical reduction and mitigation of mutagenicity 129
Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. 128
Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations 126
Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. 125
The natural history of gastro-esophageal reflux disease: A comprehensive review 124
Epidemiology and natural history of gastroesophageal reflux disease 124
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications 124
Letter: it is time to adopt new objective parameters to accurately identify patients with functional heartburn 122
Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. 120
Regression of Fibrosis After DAAs Treatment of Patients with HCV Cirrhosis: Transposability to Non-Decompensated Patients 117
Relevance of measuring substances in bronchoalveolar lavage fluid for detecting aspiration-associated extraesophageal reflux disease 116
Esophagogastric junction morphology is associated with a positive impedance-pH monitoring in patients with GERD 113
Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals 113
Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. 112
Pathophysiological studies are mandatory to understand the benefit of proton pump inhibitors in patients with idiopathic pulmonary fibrosis 111
Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis 111
Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation 111
Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value? 110
Esophageal motility abnormalities in gastroesophageal reflux disease 106
Impedance-detected symptom association and number of reflux episodes as pre-treatment parameters that predict outcomes of gastroesophageal reflux disease patients 104
Course of oesophageal varices and performance of non-invasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease 103
Overweight is a risk factor for both erosive and non-erosive reflux disease. 103
NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis 101
Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV 98
Effects of bariatric surgery on the esophagus 97
Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data 97
Applicability of Parameters for the Non-Invasive Diagnosis of Esophageal Varices Needing Treatment to Cured HCV Patients 96
Association between esophageal motor disorders and pulmonary involvement in patients affected by systemic sclerosis: a retrospective study 95
Updates in the field of non-esophageal gastroesophageal reflux disorder 95
Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered 93
Possible connection between gastroesophageal reflux and interstitial pulmonary fibrosis in patients with systemic sclerosis. 91
Achalasia and Obstructive Motor Disorders Are Not Uncommon in Patients with Eosinophilic Esophagitis 87
Review article – esophageal reflux hypersensitivity: Non-GERD or still GERD? 87
The Lyon Consensus: Does it differ from the previous ones? 86
Bile reflux in patients with nerd is associated with more severe heartburn and lower values of mean nocturnal baseline impedance and chemical clearance 86
Hepatocellular Carcinoma Intermediate Stage Subclassification Systems: One, None, and One Hundred Thousand 85
null 83
The prevention of NSAID-induced gastric ulcers is a firmly established PPI indication 83
Vonoprazan fumarate for the management of acid-related diseases 82
Nonacid Reflux Is Able to Determine Microscopic Esophagitis in Non-Erosive Reflux Disease (NERD) Patients. 79
Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy 77
Expression of Epidermal Growth Factor Receptor in patients with gastro-oesophageal reflux disease and in those with Systemic Sclerosis 76
A SIGE-SINGEM-AIGO technical review on the clinical use of esophageal reflux monitoring 73
Diabetes Medications and Risk of Hepatocellular Carcinoma 73
Can High-Frequency Intraoral Ultrasound Predict Histological Risk Factors in Oral Squamous Cell Carcinoma? A Preliminary Experience 72
Pharmacotherapies in eosinophilic esophagitis: state of the art 72
Esophageal motor disorders across ages: A retrospective multicentric analysis 68
Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? 68
Comparison of the Safety and Efficacy of Ustekinumab and Vedolizumab in Patients with Crohn’s Disease: A Systematic Review and Meta-Analysis of Propensity Score Matched Cohort Studies 67
Dietary Management of Eosinophilic Esophagitis: Tailoring the Approach 67
Presence of basal cell hyperplasia and dilatation of intercellular spaces and their association with baseline impedance values in patients with positive symptom association despite normal acid exposure further supports their role in symptoms generation in NERD 66
Risk factors for bleeding following oesophageal band ligation: Providing further evidence to ameliorate clinical practice 64
Prevalence of Lactose Intolerance in Patients with Hashimoto Thyroiditis and Impact on LT4 Replacement Dose 63
Evaluation of the pathophysiological association between the GERD and OSAS: Esophageal pH-monitoring results beyond Lyon criteria 62
Prevention Strategies for Esophageal Cancer—An Expert Review 62
An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders 61
The 1st EoETALY Consensus on the Diagnosis and Management of Eosinophilic Esophagitis – Definition, Clinical Presentation and Diagnosis 60
Advancements in the use of 24-hour impedance-pH monitoring for GERD diagnosis 58
Applying Lyon consensus criteria in the work‐up of patients with extra‐oesophageal symptoms – A multicentre retrospective study 58
Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease? 57
COVID‐19 and liver disease: not all evil comes to harm 56
Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro-oesophageal reflux disease according to Lyon Consensus 55
Sleeve gastrectomy may double the risk of esophageal adenocarcinoma in morbidly obese patients 54
Diagnostic delay and misdiagnosis in eosinophilic oesophagitis 54
Albumin-bilirubin score in non-malignant liver diseases should be properly validated 52
Food Intolerances, Food Allergies and IBS: Lights and Shadows 51
The 1st EoETALY Consensus on the Diagnosis and Management of Eosinophilic Esophagitis–Current Treatment and Monitoring 51
Clopidogrel-Induced Eosinophilic Colitis 50
Expression of Epidermal Growth Factor receptor (EGFR) in Systemic Sclerosis patients (SSc) and Gastro-oesophageal Reflux Disease (GORD) 50
Esophageal dysmotility in patients with eosinophilic esophagitis: pathogenesis, assessment tools, manometric characteristics, and clinical implications 49
Endoscopic Management of Eosinophilic Esophagitis: A Narrative Review on Diagnosis and Treatment 48
Proactive Measures Aimed at Improving Appropriateness of Use of Proton Pump Inhibitors in Clinical Practice 48
Refractoriness to Treatment Suggests That Clinical Evaluation Should Go Beyond the Diagnosis of Reflux Disease 47
The Clinical Spectrum of Gastroesophageal Reflux Disease: Facts and Fictions 46
Evaluating Vonoprazan for the treatment of erosive GERD and heartburn associated with GERD in adults 45
Totale 10.180
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.556
article - articoli 43.089
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 467
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.112
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021634 0 0 0 0 56 88 41 124 76 105 66 78
2021/20221.036 102 27 67 95 33 104 32 229 66 121 36 124
2022/20231.013 105 100 19 87 177 131 6 85 177 5 110 11
2023/2024726 25 74 8 100 54 124 61 21 32 36 64 127
2024/20252.467 136 138 116 164 266 295 200 398 117 96 272 269
2025/20261.904 555 178 492 522 157 0 0 0 0 0 0 0
Totale 11.373